Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | FPR3 | P25089 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9937183 | 0.82 | MEN1 (0.48) | MEN1ALDH1A1MAPTKMT2AUSP30 | |
| SCHEMBL1439214 | 0.82 | MEN1 (0.48) | MEN1ALDH1A1MAPTKMT2AUSP30 | |
| SCHEMBL1250472 | 0.82 | ALDH1A1 (0.35) | ALDH1A1MAPTCA1CA2 | |
| SCHEMBL17970096 | 0.81 | ALDH1A1 (0.46) | MEN1ALDH1A1MAPTKMT2AUSP30 | |
| SCHEMBL25472021 | 0.79 | USP30 (0.53) | MEN1ALDH1A1MAPTKMT2AUSP30 | |
| SCHEMBL8010277 | 0.79 | MEN1 (0.49) | MEN1ALDH1A1MAPTKMT2AUSP30 | |
| SCHEMBL20477490 | 0.79 | MEN1 (0.49) | MEN1ALDH1A1MAPTKMT2AUSP30 | |
| SCHEMBL25472053 | 0.79 | USP30 (0.53) | MEN1ALDH1A1MAPTKMT2AUSP30 | |
| SCHEMBL1420850 | 0.78 | ALDH1A1 (0.51) | MEN1ALDH1A1MAPTKMT2AUSP30 | |
| SCHEMBL12991276 | 0.78 | ALDH1A1 (0.51) | MEN1ALDH1A1MAPTKMT2AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178554-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2012-05-15 | — | — | US | disclosed |
| US-20110245254-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-06 | — | — | US | disclosed |
| US-20110213147-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2011-09-01 | — | — | US | disclosed |
| US-20110021772-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2011-01-27 | — | — | US | disclosed |
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | NOVEXEL (FR) | 2010-02-25 | — | — | US | disclosed |
| US-7612087-B2 | Therapy for bacteria infections | NOVEXEL (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090215747-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | AVENTIS PHARMA S.A. (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20050020572-A1 | Heterocyclic compounds as inhibitors of beta-lactamases | AVENTIS PHARMA S.A. (FR) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245254-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | MEN1 814/4885ALDH1A1 380/4885MAPT 3311/4885 |
| US-20110213147-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | MEN1 434/4885ALDH1A1 2392/4885MAPT 3574/4885 |
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | MEN1 814/4885ALDH1A1 380/4885MAPT 3311/4885 |
| US-20050020572-A1 | Heterocyclic compounds as inhibitors of beta-lactamases | BACE1, GAA, CEL | MEN1 814/4885ALDH1A1 380/4885MAPT 3311/4885 |
| US-20110021772-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | MEN1 434/4885ALDH1A1 2392/4885MAPT 3574/4885 |
| US-20090215747-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | MEN1 814/4885ALDH1A1 380/4885MAPT 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.